Literature DB >> 9723820

Lacidipine: effects on vascular pressor responses throughout the dosage interval in normotensive subjects.

S Ueda1, R Donnelly, V Panfilov, A D Morris, H L Elliott.   

Abstract

AIMS: To assess the duration and consistency of the pharmacological activity of the dihydropyridine calcium antagonist drug, lacidipine.
METHODS: Eight healthy normotensive young males participated in a double-blind randomised crossover comparison of single and multiple doses (for 2 weeks) of lacidipine and placebo. The calcium antagonist effects were quantified at 2, 6 and 24 h post dose by the extent of the attenuation of the pressor responses to the intravenous administration of the vasoconstrictors angiotensin II and noradrenaline.
RESULTS: After 2 weeks of treatment, lacidipine consistently and significantly attenuated the pressor responses to both agents at 2 h post dose. At 6 and 24 h post dose there was a significant and progressive decline in the effectiveness of lacidipine in attenuating the pressor responses and for the response to angiotensin II there was no statistically significant effect at either 6 or 24 h post dose.
CONCLUSIONS: These results indicate that there is an obvious 'peak' in the pharmacological activity of lacidipine at about 2 h post dose and that this activity is not fully and consistently maintained throughout 24 h.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9723820      PMCID: PMC1873659          DOI: 10.1046/j.1365-2125.1998.00760.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Ambulatory blood pressure monitoring in the assessment of antihypertensive treatment: 24-h blood pressure control with lacidipine once a day.

Authors:  P Palatini; M Penzo; G Guzzardi; M Anaclerio; A C Pessina
Journal:  J Hypertens Suppl       Date:  1991-12

Review 2.  Clinical pharmacology of lacidipine.

Authors:  S T Hall; S M Harding; G L Evans; M Pellegatti; P Rizzini
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

Review 3.  Selection of initial and maintenance dosages for lacidipine, a new once-daily calcium antagonist for the treatment of hypertension.

Authors:  M Perelman
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

Review 4.  The pressor dose-response in clinical cardiovascular pharmacology.

Authors:  D J Sumner; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

5.  The effect of calcium channel blockers on alpha 1- and alpha 2-adrenoceptor-mediated vascular responsiveness in man.

Authors:  H L Elliott; F Pasanisi; D J Sumner; J L Reid
Journal:  J Hypertens Suppl       Date:  1985-12

6.  Role of plasma kallikrein in the proteolytic activation of the renin-angiotensin system.

Authors:  F H Derkx; B N Bouma; H L Tan-Tjiong; A J Man in 't Veld; J H de Bruyn; G J Wenting; M A Schalekamp
Journal:  Clin Exp Hypertens       Date:  1980       Impact factor: 1.749

7.  Effect of calcium channel blockers on adrenergic and nonadrenergic vascular responses in man.

Authors:  F Pasanisi; H L Elliott; P A Meredith; D J Sumner; J L Reid
Journal:  J Cardiovasc Pharmacol       Date:  1985 Nov-Dec       Impact factor: 3.105

8.  Nifedipine and alpha adrenoceptor antagonism.

Authors:  M B Murphy; M J Brown; A J Scriven; D J Heavey; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

9.  Molecular interaction between lacidipine and biological membranes.

Authors:  L G Herbette; G Gaviraghi; T Tulenko; R P Mason
Journal:  J Hypertens Suppl       Date:  1993-03

10.  A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices.

Authors:  A D Bainbridge; O Herlihy; P A Meredith; H L Elliott
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more
  1 in total

Review 1.  Lacidipine: a review of its use in the management of hypertension.

Authors:  Paul L McCormack; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.